ALT Altimmune: Total Company Value-to-Revenue Ratio

Altimmune Inc (ALT) - corporate logo

Altimmune, Inc. (ALT) maintains high operational efficiency through an optimized contract manufacturing network. The company's enterprise value-to-revenue valuation reflects current trends, where 1515666.67 represents the current metric level. However, success depends on the outcome of clinical trials and market demand. The environmental footprint remains minimal due to outsourcing and adherence to laboratory safety standards.

Altimmune Corp (ALT) EV/Sales Multiple: for the period 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for Altimmune (ALT)

- market price and analyst price targets:
Fundamental company valuation:ALT (altimmune.com)
Flagship merchandise of altimmune.com

This ratio determines the market value of the business, accounting for net debt relative to annual turnover. By analyzing the EV-to-revenue metric of the company, an investor assesses the efficiency of asset monetization without distortions from the capital structure. The metric is calculated as the ratio of the total enterprise value to sales volume. For Altimmune, Inc. (ALT), this indicator reflects the capital intensity of peptide development. Dependence on external contract manufacturers makes cost monitoring critical for assessing operational resilience.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple aardvarktherapeutics.com AARD|SGMT: Company Value to Revenue|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)